Active — Not RecruitingPhase 2

A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

China195 participantsStarted 2025-12-22

Plain-language summary

To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

Age range40 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Myocardial infarction, unstable angina, or stroke within the past 6 months;
✕. Unstable or life-threatening arrhythmias requiring intervention within the past 3 months;
✕. New York Heart Association (NYHA) Class III-IV heart failure.
✕. Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 2 × Upper Limit of Normal (ULN); alkaline phosphatase \> 2 × ULN; total bilirubin \> 1.5 × ULN;
✕. Estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \< 60 mL/min/1.73m².

Change of the maximum value of Forced Expiratory Volume in the first second (FEV1)

Timeframe: From baseline to four weeks after treatment

NCT IDNCT07252908

SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05